NIPT Menu and Technology Offerings

Project Overview

A leading diagnostics player asked DeciBio to characterize the evolving NIPT market to help inform strategic positioning regarding menu offerings and technological approach

DeciBio Approach

Secondary Research

Gathered data around annual birth rates and average age of first-time mothers across ~10 ex-U.S. regions
Reviewed product specifications of competing vendors to understand menu offerings, test prices and technological approaches
Conducted clinical trial analysis of ~50 active trials related to NIPT to evaluate interest in testing for conditions beyond T21, T18, T13

‍Primary Research

Conducted 11 in-depth stakeholder interviews with HCPs (OBGYNs and MFMs), lab directors, and industry KOLs in multiple settings across APAC, Europe and the Middle East

At a glance

Stakeholder Interviews

>10

Countries Researched and Modelled

NIPT-related Clinical Trials Analyzed

Outcomes

Key takeaways from DeciBio’s presentation to the client team included:

Bifurcation of testing is real and currently vendor-driven in NIPT
Significant regional nuances exist, with high willingness-to-pay among certain segments of the market
Client should consider broadening its menu offerings in order to remain competitive and continue to maintain its global position

Timeline

4 weeks

Geographic Scope

Singapore, Taiwan, Korea, Czech Republic and other EU countries

Industry

capabilities

Voice-Of-Customer Research

Cell and Gene Therapy Services Landscape Assessment

Cell and Gene Therapy Service Market Opportunity Assessment

Synthetic Oligonucleotides Market Sizing